Evidence map›Paper›PMID 32706859›Full record

Trial reportClinical infectious diseases : an official publication of the Infectious Diseases Society of America2021

Remdesivir for Severe Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard of Care.

Susan A Olender, Katherine K Perez, Alan S Go, Bindu Balani, Eboni G Price-Haywood, Nirav S Shah, Su Wang, Theresa L Walunas, Shobha Swaminathan, Jihad Slim and 24 more

Registry-linked trialOpen access · hybridAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04292899 (A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir), which is not on this map. Cited by 96 papers, 13 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
96citing papers in PubMed, 13 pooled it
3.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04292899 phase3completednot on this map

A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe COVID-19

TypeinterventionalSponsorGilead SciencesRan2020 to 2020Enrolled4,891ConditionsCOVID-19ArmsRemdesivir, Standard of Care
3 · Its place in the literature

Who cites it

96 citing papers in PubMed, 13 syntheses or guidelines pooled it, 171 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Remdesivir for the treatment of COVID-19.The Cochrane database of systematic reviews · 2023
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Remdesivir for the treatment of COVID-19.The Cochrane database of systematic reviews · 2021
    Pooled it
  7. Pooled it
  8. Asthma in patients with coronavirus disease 2019: A systematic review and meta-analysis.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2021
    Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. RETRACTED: Remdesivir Efficacy in COVID-19 Treatment: A Randomized Controlled Trial.The American journal of tropical medicine and hygiene · 2021
    Trial
  15. Adverse drug reactions associated with COVID-19 management.Naunyn-Schmiedeberg's archives of pharmacology · 2024
    Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review

36 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

34 authors at 20 institutions in 7 countries.

Susan A OlenderDivision of Infectious Diseases, Department of Internal Medicine, Columbia University Irving Medical Center, New York, New York, USA.
Katherine K PerezHouston Methodist, Houston, Texas, USA.
Alan S GoDivision of Research, Kaiser Permanente Northern California, Oakland, California, USA.
Bindu BalaniHackensack University Medical Center, Hackensack, New Jersey, USA.
Eboni G Price-HaywoodOchsner Health System and Ochsner Clinical School, New Orleans, Louisiana, USA.
Nirav S ShahNorthShore University Health System, Evanston, Illinois, USA.
Su WangSaint Barnabas Medical Center, RWJBarnabas Medical Group, Livingston, New Jersey, USA.
Theresa L WalunasNorthwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Shobha SwaminathanRutgers New Jersey Medical School, Newark, New Jersey, USA.
Jihad SlimPrime Healthcare Services, St Michael's LLC, Newark, New Jersey, USA.
BumSik ChinNational Medical Center, Seoul, South Korea.
Stéphane De WitNEAT ID Foundation, CHU Saint Pierre, Brussels, Belgium.
Shamim M AliNEAT ID Foundation, Chelsea and Westminster Hospital, London, United Kingdom.
Alex Soriano ViladomiuHospital Clinic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain.
Philip RobinsonHoag Memorial Hospital Presbyterian, Newport Beach, California, USA.
Robert L GottliebBaylor University Medical Center Dallas, Dallas, Texas, USA.
Tak Yin Owen TsangPrincess Margaret Hospital, Kwai Chung, Hong Kong.
I-Heng LeeGilead Sciences, Foster City, California, USA.
Hao HuGilead Sciences, Causeway Bay, Hong Kong.
Richard H HaubrichGilead Sciences, Foster City, California, USA.
Anand P ChokkalingamGilead Sciences, Foster City, California, USA.
Lanjia LinGilead Sciences, Foster City, California, USA.
Lijie ZhongGilead Sciences, Foster City, California, USA.
B Nebiyou BekeleGilead Sciences, Foster City, California, USA.
Robertino Mera-GilerGilead Sciences, Foster City, California, USA.
Chloé PhulpinGilead Sciences, Stockley Park, Uxbridge, United Kingdom.
Holly EdgarGilead Sciences, Stockley Park, Uxbridge, United Kingdom.
Joel GallantGilead Sciences, Foster City, California, USA.
Helena Diaz-CuervoGilead Sciences, Madrid, Spain.
Lindsey E SmithGilead Sciences, Foster City, California, USA.
Anu O OsinusiGilead Sciences, Foster City, California, USA.
Diana M BrainardGilead Sciences, Foster City, California, USA.
Jose I BernardinoHospital La Paz, IdiPAZ, Madrid, Spain.
GS-US-540–5773 and GS-US-540–5807 Investigators
Gilead Sciences (United States) · USGilead Sciences (United Kingdom) · GBBaylor University Medical Center · USCentre Hospitalier Universitaire de Saint-Pierre · BEChelsea and Westminster Hospital · GBColumbia University Irving Medical Center · USGilead Sciences (Spain) · ESHackensack University Medical Center · USHoag Memorial Hospital Presbyterian · USHospital Clínic de Barcelona · ESHospital La Paz Institute for Health Research · ESHouston Methodist · USKaiser Permanente · USKwai Chung Hospital · CNNational Medical Center · KRNorthShore University HealthSystem · USNorthwestern University · USOchsner Health System · USRutgers, The State University of New Jersey · USSaint Barnabas Medical Center · US

Funding

Northwestern University Clinical and Translational Science Institute (NUCATS)UL1TR001422 · NCATS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI D'AQUILA, RICHARD · 2015 to 2023
$56.8M
Gilead SciencesNCATS NIH HHS UL1 TR001422
6 · The paper itself

Abstract

backgroundWe compared the efficacy of the antiviral agent, remdesivir, versus standard-of-care treatment in adults with severe coronavirus disease 2019 (COVID-19) using data from a phase 3 remdesivir trial and a retrospective cohort of patients with severe COVID-19 treated with standard of care.

methodsGS-US-540-5773 is an ongoing phase 3, randomized, open-label trial comparing two courses of remdesivir (remdesivir-cohort). GS-US-540-5807 is an ongoing real-world, retrospective cohort study of clinical outcomes in patients receiving standard-of-care treatment (non-remdesivir-cohort). Inclusion criteria were similar between studies: patients had confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, were hospitalized, had oxygen saturation ≤94% on room air or required supplemental oxygen, and had pulmonary infiltrates. Stabilized inverse probability of treatment weighted multivariable logistic regression was used to estimate the treatment effect of remdesivir versus standard of care. The primary endpoint was the proportion of patients with recovery on day 14, dichotomized from a 7-point clinical status ordinal scale. A key secondary endpoint was mortality.

resultsAfter the inverse probability of treatment weighting procedure, 312 and 818 patients were counted in the remdesivir- and non-remdesivir-cohorts, respectively. At day 14, 74.4% of patients in the remdesivir-cohort had recovered versus 59.0% in the non-remdesivir-cohort (adjusted odds ratio [aOR] 2.03: 95% confidence interval [CI]: 1.34-3.08, P < .001). At day 14, 7.6% of patients in the remdesivir-cohort had died versus 12.5% in the non-remdesivir-cohort (aOR 0.38, 95% CI: .22-.68, P = .001).

conclusionsIn this comparative analysis, by day 14, remdesivir was associated with significantly greater recovery and 62% reduced odds of death versus standard-of-care treatment in patients with severe COVID-19. CLINICAL TRIALS REGISTRATION: NCT04292899 and EUPAS34303.

Indexed as

COVID-19 Drug TreatmentAdenosine MonophosphateAdultAlanineAntiviral AgentsCohort StudiesHumansOxygen SaturationRetrospective StudiesSARS-CoV-2Standard of CareTreatment OutcomeAdenosine MonophosphateAlanineAntiviral Agentsremdesivirantiviral treatmentremdesivirSARS-CoV-2severe COVID-19

Identifiers

PMID32706859
PMCPMC7454434
OpenAlexW3043870823

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.